Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07093892

Cohort Study on Cognitive Decline in Elderly

Alzheimer's Disease (AD) prevention and control currently face severe challenges, with limited treatment options and effectiveness available. Once the disease progresses to the AD stage, it is essentially irreversible. Before the onset of AD, there is a prolonged asymptomatic period and a stage of mild cognitive impairment (MCI), which represents a critical window for early screening, diagnosis, and intervention. Therefore, early screening, diagnosis, and intervention during the MCI stage are crucial for slowing or halting the rising trend of AD and alleviating its disease burden.

This study plans to enroll elderly individuals from communities around Peking University Third Hospital to establish a prospective cohort. Participants will undergo cognitive assessments and blood biomarker testing, followed by a three-year follow-up and management program. The study aims to obtain epidemiological data on MCI and AD in community populations, investigate the relationships between known risk factors, genetic factors, and blood biomarkers with disease progression, explore additional biomarkers, and develop predictive models. These efforts will contribute to promoting early diagnosis, early intervention, and improved prognosis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

55 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 55 years or older;
  • No diagnosis of Alzheimer's disease (AD);
  • Participants are able to complete cognitive tests, provide biological samples, undergo neuroimaging examinations, and cooperate throughout the entire study process;
  • Signed informed consent.

Exclusion criteria

  • Participants with severe mental illness, tumor-related cachexia, severe hepatic or renal insufficiency, or other major physical conditions that may hinder cooperation with the examinations;
  • Participants who are unable to complete the required assessments due to visual or hearing impairments;
  • Contraindications for MRI or other study-related examinations.

Treatment and study plan

Primary outcomes

  1. The change of MMSE

    Time frame: 3 years

    MMSE is a 30-point questionnaire used to measure cognitive function

  2. The change of MoCA

    Time frame: 3 years

    MoCA is a 30-point questionnaire used to measure cognitive function

Study contacts

Contact information is provided by the study sponsor or research team.

Qiong Yang

CONTACT

[email protected]

+861082265024

Sponsors and collaborators

Lead sponsor

Peking University Third Hospital

Other

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Jul 30, 2025
Registry last updated
Jul 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.